— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.
— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.
— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.
— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.
— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.
— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.
— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.
Cintas Corporation (NASDAQ: CTAS) reported first quarter 2021 earnings results today. Revenue was $1.75 billion, down 3.6% year-over-year. Net income rose 19% to $300 million, or $2.78 per share, from
General Mills (NYSE: GIS) reported first-quarter 2020 financial results before the opening bell on Wednesday. The company reported a 9% increase in Q1 revenues to $4.36 billion, beating the Wall
JinkoSolar Holding Co., Ltd. (NYSE: JKS) reported second quarter 2020 earnings results today. Total revenues increased 22.2% year-over-year to RMB8.45 billion ($1.20 billion), exceeding the company’s guidance of $1.10 billion to $1.18 billion. The growth was